Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedAug 25, 2025
DataAggregated Company Financials
Companies549
  • 7D0.3%
  • 3M10.9%
  • 1Y-7.9%
  • YTD6.4%

Over the last 7 days, the Biotech industry has remained flat. As for the longer term, the industry has declined 7.9% in the last year. Looking forward, earnings are forecast to grow by 26% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 25 Aug 2025US$1.1tUS$163.6b-US$18,584,724,159.6315.1x-57.8x6.6x
Wed, 23 Jul 2025US$961.0bUS$155.2b-US$23,253,955,254.0116.5x-41.3x6.2x
Fri, 20 Jun 2025US$929.9bUS$155.9b-US$23,930,083,012.0216.9x-38.9x6x
Sun, 18 May 2025US$895.3bUS$155.9b-US$24,392,718,921.6016.3x-36.7x5.7x
Tue, 15 Apr 2025US$740.5bUS$119.2b-US$36,459,397,381.9019.9x-20.3x6.2x
Thu, 13 Mar 2025US$834.6bUS$118.7b-US$37,659,545,163.6818.4x-22.2x7x
Sat, 08 Feb 2025US$857.1bUS$117.3b-US$30,948,989,158.0417.2x-27.7x7.3x
Mon, 06 Jan 2025US$980.2bUS$149.6b-US$26,354,792,434.1217x-37.2x6.6x
Wed, 04 Dec 2024US$1.0tUS$149.9b-US$26,584,927,055.4016.5x-39.1x6.9x
Fri, 01 Nov 2024US$1.1tUS$147.3b-US$30,454,139,694.2717.1x-34.7x7.2x
Sun, 29 Sep 2024US$893.6bUS$113.2b-US$36,006,680,210.7121.3x-24.8x7.9x
Tue, 27 Aug 2024US$909.0bUS$113.1b-US$35,851,266,005.4623.3x-25.4x8x
Thu, 25 Jul 2024US$1.2tUS$164.5b-US$28,090,976,401.9328.2x-43x7.3x
Sat, 22 Jun 2024US$1.1tUS$164.4b-US$27,943,646,272.0028.1x-41.1x7x
Mon, 20 May 2024US$1.1tUS$164.6b-US$26,835,738,666.6423.9x-42.8x7x
Wed, 17 Apr 2024US$1.1tUS$164.2b-US$23,402,696,044.0520.5x-46.3x6.6x
Fri, 15 Mar 2024US$1.2tUS$167.4b-US$22,100,849,384.5416.3x-54.1x7.1x
Sun, 11 Feb 2024US$1.2tUS$169.3b-US$26,263,046,791.8719.8x-44.2x6.9x
Tue, 09 Jan 2024US$1.4tUS$204.8b-US$22,499,844,981.0020.8x-63.1x6.9x
Thu, 07 Dec 2023US$1.3tUS$204.6b-US$22,056,080,007.0019.4x-58.1x6.3x
Sat, 04 Nov 2023US$1.2tUS$206.7b-US$20,531,174,316.0018.8x-60.4x6x
Mon, 02 Oct 2023US$1.3tUS$207.4b-US$13,122,605,528.0017.1x-95.8x6.1x
Wed, 30 Aug 2023US$1.3tUS$207.6b-US$12,432,896,963.0017.8x-103.8x6.2x
Fri, 28 Jul 2023US$1.1tUS$186.8b-US$16,232,166,533.0014.3x-69.6x6x
Sun, 25 Jun 2023US$1.1tUS$186.2b-US$16,162,116,001.0013.6x-70.3x6.1x
Tue, 23 May 2023US$1.2tUS$186.0b-US$15,902,975,009.0013.3x-72.9x6.2x
Thu, 20 Apr 2023US$1.2tUS$198.4b-US$3,264,741,817.0013.6x-362.5x6x
Sat, 18 Mar 2023US$1.1tUS$199.2b-US$3,900,694,523.0013.2x-286.4x5.6x
Mon, 13 Feb 2023US$1.2tUS$202.7b-US$211,129,546.0016.4x-5476.8x5.7x
Wed, 11 Jan 2023US$1.2tUS$203.5bUS$1.7b14.1x695.4x5.7x
Fri, 09 Dec 2022US$1.2tUS$202.7bUS$1.4b14.9x819.9x5.8x
Sun, 06 Nov 2022US$1.1tUS$204.6bUS$3.6b14.2x299.5x5.3x
Tue, 04 Oct 2022US$1.0tUS$206.2bUS$5.5b14.6x189.3x5x
Thu, 01 Sep 2022US$1.0tUS$206.4bUS$7.3b14.1x140x5x
Price to Earnings Ratio

140x


Total Market Cap: US$1.0tTotal Earnings: US$7.3bTotal Revenue: US$206.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average 40.2x202320242025
Current Industry PE
  • Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.4x.
Past Earnings Growth
  • Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
  • Revenues have also declined 7.5% per year, which is driving profits down.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.47%
Healthcare1.70%
Biotech0.30%
Biotech0.30%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ABBV AbbVieUS$210.602.0%
+US$7.1b		6.7%PE99.9x
REGN Regeneron PharmaceuticalsUS$589.482.7%
+US$1.6b		-50.9%PE13.7x
VRTX Vertex PharmaceuticalsUS$395.121.3%
+US$1.3b		-18.1%PE27.8x
INSM InsmedUS$131.883.6%
+US$974.4m		75.3%PS70x
CAI Caris Life SciencesUS$39.309.3%
+US$942.1m		n/aPS20.7x

Latest News

INSM
US$131.88
Insmed
7D
3.6%
1Y
75.3%

Brensocatib's 2025 Launch Will Transform Bronchiectasis Care

Insmed’s consensus price target has surged to $148.44, driven by the FDA approval and strong commercial prospects for Brinsupri, expanded pipeline potential, and robust Phase 2 results for TPIP—underscoring significant upward revisions in revenue and profit expectations. Analyst Commentary Bullish analysts are raising price targets following FDA approval of Brinsupri as the first therapy for non-cystic fibrosis bronchiectasis, citing a broad label with both doses approved, clean safety profile, and inclusion of favorable FEV1 and secondary endpoint data in prescribing information.
NTRA
US$165.60
Natera
7D
2.8%
1Y
40.2%
MDGL
US$414.68
Madrigal Pharmaceuticals
7D
5.9%
1Y
62.1%

Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) 30% Price Boost Is Out Of Tune With Revenues

Aug 22
Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) 30% Price Boost Is Out Of Tune With Revenues
ALNY
US$454.38
Alnylam Pharmaceuticals
7D
-0.5%
1Y
68.8%
ABBV
US$210.60
AbbVie
7D
2.0%
1Y
6.7%
ONC
US$313.67
BeOne Medicines
7D
-1.8%
1Y
57.4%
REGN
US$589.48
Regeneron Pharmaceuticals
7D
2.7%
1Y
-50.9%
VKTX
US$26.00
Viking Therapeutics
7D
-38.2%
1Y
-60.3%
BNTX
US$110.88
BioNTech
7D
-1.5%
1Y
26.7%
LEGN
US$35.56
Legend Biotech
7D
-5.0%
1Y
-37.2%
GILD
US$114.77
Gilead Sciences
7D
-2.7%
1Y
49.1%
CAI
US$39.30
Caris Life Sciences
7D
9.3%
1Y
n/a
ETHZ
US$3.30
ETHZilla
7D
-55.5%
1Y
68.4%
AMGN
US$293.72
Amgen
7D
0.4%
1Y
-10.1%

Statutory Profit Doesn't Reflect How Good Amgen's (NASDAQ:AMGN) Earnings Are

Aug 13
Statutory Profit Doesn't Reflect How Good Amgen's (NASDAQ:AMGN) Earnings Are
VRTX
US$395.12
Vertex Pharmaceuticals
7D
1.3%
1Y
-18.1%
MRNA
US$27.12
Moderna
7D
-3.5%
1Y
-66.8%